HBCNF logo

HealthBeacon plc (HBCNF)

Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

HBCNF steht fuer HealthBeacon plc, ein Healthcare-Unternehmen mit einem Kurs von $ (Marktkapitalisierung 0). Bewertet mit 44/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.

Zuletzt analysiert: 18. März 2026
44/100 KI-Bewertung

HealthBeacon plc (HBCNF) Gesundheitswesen & Pipeline-Uebersicht

CEOKieran Daly
Mitarbeiter70
HauptsitzDublin, IE
IPO-Jahr2022

HealthBeacon plc offers a digital therapeutics platform for managing injectable medications at home, leveraging technology to improve patient adherence and outcomes. The company operates in Europe, the United States, and Ireland, providing medication management, sharps disposal, and AI-driven data analytics within the healthcare information services sector.

Datenherkunft | Finanzdaten Quantitative Analyse NASDAQ Analyse: 18. März 2026

Investmentthese

HealthBeacon plc presents a notable research candidate within the growing digital therapeutics market. The company's focus on improving medication adherence for injectable medications addresses a significant unmet need. Key value drivers include expansion into new geographic markets and partnerships with pharmaceutical companies and healthcare providers. The company's negative P/E ratio of -0.55 and a negative profit margin of -588.6% indicate that the company is not currently profitable. The company's low gross margin of 6.0% suggests challenges in achieving profitability. Upcoming catalysts include potential regulatory approvals and new product launches. The company's beta of -0.29 suggests lower volatility than the market.

Basierend auf FMP-Finanzdaten und quantitativer Analyse

Wichtige Highlights

  • HealthBeacon plc operates in the digital therapeutics market, focusing on medication adherence for injectable medications.
  • The company's injection care management system includes medication reminders, sharps disposal, and data analytics.
  • HealthBeacon's solutions are available in Europe, the United States, and Ireland.
  • The company's market capitalization is approximately $0.01 billion.
  • HealthBeacon's gross margin is 6.0%.

Wettbewerber & Vergleichsunternehmen

Staerken

  • Proprietary technology for medication adherence.
  • Focus on injectable medications, a growing market.
  • Partnerships with pharmaceutical companies.
  • AI-driven data analytics for personalized interventions.

Schwaechen

  • Limited financial resources.
  • Small market capitalization.
  • Negative profitability.
  • Reliance on partnerships for growth.

Katalysatoren

  • Upcoming: Potential regulatory approvals for new products and services.
  • Ongoing: Expansion into new geographic markets.
  • Ongoing: Partnerships with pharmaceutical companies to integrate its solutions into their drug delivery programs.
  • Ongoing: Development of new products and services to address other aspects of medication management.
  • Ongoing: Integration with electronic health records (EHRs) to provide healthcare providers with a more complete view of their patients' medication adherence.

Risiken

  • Potential: Competition from established healthcare companies.
  • Potential: Regulatory hurdles for digital therapeutics.
  • Potential: Data privacy and security concerns.
  • Potential: Reimbursement challenges for digital health solutions.
  • Ongoing: Limited financial resources may hinder growth initiatives.

Wachstumschancen

  • Expansion into new geographic markets: HealthBeacon has the opportunity to expand its presence in Europe and the United States, as well as enter new markets in Asia and Latin America. The global market for digital therapeutics is projected to reach $9.6 billion by 2027, providing a significant growth opportunity for the company. Timeline: Ongoing.
  • Partnerships with pharmaceutical companies: HealthBeacon can partner with pharmaceutical companies to integrate its medication adherence solutions into their drug delivery programs. This can help pharmaceutical companies improve patient outcomes and increase sales. The pharmaceutical industry spends billions of dollars annually on patient support programs, creating a potential revenue stream for HealthBeacon. Timeline: Ongoing.
  • Development of new products and services: HealthBeacon can develop new products and services to address other aspects of medication management, such as medication reconciliation and drug interactions. The market for medication management solutions is growing rapidly, driven by the increasing complexity of medication regimens. Timeline: Ongoing.
  • Integration with electronic health records (EHRs): HealthBeacon can integrate its medication adherence data with EHRs to provide healthcare providers with a more complete view of their patients' medication adherence. This can help healthcare providers make more informed treatment decisions. The adoption of EHRs is increasing rapidly, creating a growing demand for integrated medication adherence solutions. Timeline: Ongoing.
  • Leveraging AI and machine learning: HealthBeacon can leverage AI and machine learning to personalize medication adherence interventions and predict which patients are at risk of non-adherence. This can help healthcare providers target their interventions more effectively. The use of AI and machine learning in healthcare is growing rapidly, creating new opportunities for innovation. Timeline: Ongoing.

Chancen

  • Expansion into new geographic markets.
  • Development of new products and services.
  • Integration with electronic health records.
  • Increasing adoption of digital therapeutics.

Risiken

  • Competition from established healthcare companies.
  • Regulatory hurdles for digital therapeutics.
  • Data privacy and security concerns.
  • Reimbursement challenges for digital health solutions.

Wettbewerbsvorteile

  • Proprietary technology: HealthBeacon's injection care management system is protected by patents and trade secrets.
  • Data analytics: HealthBeacon's AI-driven data analytics provide valuable insights into patient adherence.
  • Partnerships: HealthBeacon has established partnerships with pharmaceutical companies and healthcare providers.

Ueber HBCNF

HealthBeacon plc, established in 2013 and headquartered in Dublin, Ireland, is a digital therapeutics company focused on improving medication adherence for patients managing injectable medications at home. The company's core product is an injection care management system that combines technology and services to support patients throughout their treatment journey. This system provides medication management reminders, safe sharps disposal devices, educational tools, and AI-driven data analytics to track adherence and persistence. HealthBeacon's solutions are available in Europe, the United States, and Ireland. The company sells and leases its medical adherence technology devices and injection care management systems to healthcare providers and patients directly. By addressing the challenges of medication adherence, HealthBeacon aims to improve patient outcomes and reduce healthcare costs associated with non-adherence.

Was das Unternehmen tut

  • Develops digital therapeutic solutions for managing injectable medications at home.
  • Provides medication management reminders to patients.
  • Offers safe and sustainable sharps disposal devices.
  • Provides educational tools to patients.
  • Utilizes AI-driven data analytics to track medication adherence.
  • Sells and leases medical adherence technology devices.
  • Offers injection care management systems.

Geschaeftsmodell

  • Sells and leases medical adherence technology devices to healthcare providers and patients.
  • Generates revenue from subscriptions to its injection care management system.
  • Partners with pharmaceutical companies to integrate its solutions into their drug delivery programs.

Branchenkontext

The healthcare information services industry is experiencing rapid growth, driven by the increasing adoption of digital health solutions and the need for improved patient outcomes. The market for digital therapeutics is projected to reach billions of dollars in the coming years. HealthBeacon plc operates in this dynamic landscape, competing with companies offering medication adherence solutions and remote patient monitoring technologies. Competitors include BNOEF (Biofrontera Inc), CDXFF (CareDx Inc), CRBKF (Cornerstone Bank), DOCRF (Doximity Inc), and FLWPF (Welltower Inc). HealthBeacon's focus on injectable medications differentiates it from some competitors.

Wichtige Kunden

  • Patients who require injectable medications for chronic conditions.
  • Healthcare providers who prescribe injectable medications.
  • Pharmaceutical companies that manufacture injectable medications.
KI-Zuversicht: 81% Aktualisiert: 18. März 2026

Finanzdaten

Chart & Info

HealthBeacon plc (HBCNF) Aktienkurs: Price data unavailable

Aktuelle Nachrichten

Keine aktuellen Nachrichten fuer HBCNF verfuegbar.

Analystenkonsens

Konsens-Bewertung

Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer HBCNF.

Kursziele

Wall-Street-Kurszielanalyse fuer HBCNF.

MoonshotScore

44/100

Was bedeutet diese Bewertung?

Der MoonshotScore bewertet das Wachstumspotenzial von HBCNF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.

Fuehrung: Kieran Daly

CEO

Kieran Daly is the Chief Executive Officer of HealthBeacon plc. His background includes experience in the healthcare and technology sectors. He has held leadership positions in various companies, focusing on commercial strategy and business development. Daly's expertise lies in driving growth and innovation in the healthcare industry. He is responsible for leading HealthBeacon's strategic direction and execution.

Erfolgsbilanz: Under Kieran Daly's leadership, HealthBeacon plc has focused on expanding its market presence in Europe and the United States. He has overseen the development and launch of new products and services, including the integration of AI-driven data analytics into the company's injection care management system. Daly has also been instrumental in forging partnerships with pharmaceutical companies and healthcare providers.

HBCNF OTC-Marktinformationen

The OTC Other tier represents the lowest tier of the OTC market, indicating that HealthBeacon plc may not meet the minimum financial or disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier may have limited financial information available to investors, and trading activity may be sporadic. Investing in companies on the OTC Other tier carries a higher degree of risk compared to companies listed on major exchanges like the NYSE or NASDAQ.

  • OTC-Stufe: OTC Other
  • Offenlegungsstatus: Unknown
Liquiditaet: Liquidity for HBCNF on the OTC market is likely limited, given its listing on the OTC Other tier. This typically translates to lower trading volumes and wider bid-ask spreads compared to stocks on major exchanges. Investors may experience difficulty in buying or selling shares quickly and at desired prices due to the limited market participation.
OTC-Risikofaktoren:
  • Limited financial disclosure: The lack of comprehensive financial information increases investment risk.
  • Low liquidity: Difficulty in buying or selling shares can lead to significant price fluctuations.
  • Higher price volatility: The combination of low liquidity and limited information can result in increased price volatility.
  • Potential for fraud or manipulation: The OTC market is subject to less regulatory oversight than major exchanges, increasing the risk of fraudulent or manipulative activities.
  • Going concern risk: Companies on the OTC Other tier may face financial difficulties and have a higher risk of going out of business.
Sorgfaltspruefung-Checkliste:
  • Verify the company's legal status and registration.
  • Obtain and review any available financial statements.
  • Assess the company's business model and competitive landscape.
  • Evaluate the management team's experience and track record.
  • Understand the company's capital structure and any outstanding debt.
  • Check for any regulatory filings or legal proceedings.
  • Consult with a qualified financial advisor.
Legitimitaetssignale:
  • Company is registered and incorporated in Ireland.
  • HealthBeacon has partnerships with established pharmaceutical companies.
  • The company has a functional website and actively promotes its products and services.
  • HealthBeacon's products address a clear need in the healthcare market.
  • Company has been in operation since 2013.

HealthBeacon plc Aktie: Wichtige Fragen beantwortet

What are the key factors to evaluate for HBCNF?

HealthBeacon plc (HBCNF) currently holds an AI score of 44/100, indicating low score. Key strength: Proprietary technology for medication adherence.. Primary risk to monitor: Potential: Competition from established healthcare companies.. This is not financial advice.

How frequently does HBCNF data refresh on this page?

HBCNF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven HBCNF's recent stock price performance?

Recent price movement in HealthBeacon plc (HBCNF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary technology for medication adherence.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider HBCNF overvalued or undervalued right now?

Determining whether HealthBeacon plc (HBCNF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying HBCNF?

Before investing in HealthBeacon plc (HBCNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding HBCNF to a portfolio?

Potential reasons to consider HealthBeacon plc (HBCNF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Proprietary technology for medication adherence.. Additionally: Focus on injectable medications, a growing market.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.

Can I buy fractional shares of HBCNF?

Yes, most major brokerages offer fractional shares of HealthBeacon plc (HBCNF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track HBCNF's earnings and financial reports?

HealthBeacon plc (HBCNF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for HBCNF earnings announcements is recommended.

Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.

Offizielle Ressourcen

Analyse aktualisiert am KI-Bewertung taeglich aktualisiert
Datenquellen & Methodik
Marktdaten bereitgestellt von Financial Modeling Prep & Yahoo Finance. KI-Analyse durch proprietaere Algorithmen von Stock Expert AI. Technische Indikatoren nach branchenueblichen Berechnungsstandards. Zuletzt aktualisiert: .

Daten dienen ausschliesslich zu Informationszwecken.

Analysehinweise
  • Information is based on available data and may be subject to change.
  • OTC market data may be less reliable than major exchange data.
  • AI analysis is pending and may provide additional insights in the future.
Datenquellen

Popular Stocks